These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 18491179

  • 1. Novel topical BoNTA (CosmeTox, toxin type A) cream used to treat hyperfunctional wrinkles of the face, mouth, and neck.
    Chajchir I, Modi P, Chajchir A.
    Aesthetic Plast Surg; 2008 Sep; 32(5):715-22; discussion 723. PubMed ID: 18491179
    [Abstract] [Full Text] [Related]

  • 2. Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes.
    Carruthers J, Carruthers A.
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S10-7. PubMed ID: 17241408
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY, North American Botox in Primary Axillary Hyperhidrosis Clinical Study Group.
    J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
    [Abstract] [Full Text] [Related]

  • 6. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
    Blumenfeld AM, Schim JD, Chippendale TJ.
    Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
    Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM, BoNTA-009 Study Group.
    Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
    [Abstract] [Full Text] [Related]

  • 9. Indications and limitations for the use of botulinum toxin for the treatment of facial wrinkles.
    Sarrabayrouse MA.
    Aesthetic Plast Surg; 2002 Sep; 26(4):233-8. PubMed ID: 12397444
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy.
    Carruthers A, Carruthers J.
    J Am Acad Dermatol; 2009 Jun; 60(6):972-9. PubMed ID: 19467368
    [Abstract] [Full Text] [Related]

  • 14. Botulinum toxin: examining duration of effect in facial aesthetic applications.
    Flynn TC.
    Am J Clin Dermatol; 2010 Jun; 11(3):183-99. PubMed ID: 20369902
    [Abstract] [Full Text] [Related]

  • 15. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT, Kailasam J, Meadors L.
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Patient-reported outcomes with botulinum neurotoxin type A.
    Carruthers A, Carruthers J.
    J Cosmet Laser Ther; 2007 Feb; 9 Suppl 1():32-7. PubMed ID: 17885884
    [Abstract] [Full Text] [Related]

  • 19. Patient satisfaction with different botulinum toxin type A formulations in the treatment of moderate to severe upper facial rhytids.
    de Boulle K.
    J Cosmet Laser Ther; 2008 Jun; 10(2):87-92. PubMed ID: 18569261
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.